These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 20870149

  • 21. Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor.
    Takasu S, Takahashi T, Okamoto S, Oriuchi N, Nakayashiki N, Okamoto K, Muramatsu H, Hayashi T, Nakahara N, Mizuno M, Wakabayashi T, Higuchi T, Endo K, Kozaki K, Miyaishi O, Saga S, Ueda R, Yoshida J, Yoshikawa K.
    J Neurooncol; 2003 Jul; 63(3):247-56. PubMed ID: 12892230
    [Abstract] [Full Text] [Related]

  • 22. Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.
    Shin IS, Lee SM, Kim HS, Yao Z, Regino C, Sato N, Cheng KT, Hassan R, Campo MF, Albone EF, Choyke PL, Pastan I, Paik CH.
    Nucl Med Biol; 2011 Nov; 38(8):1119-27. PubMed ID: 21741258
    [Abstract] [Full Text] [Related]

  • 23. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R, Govindan SV, Chen S, Reed L, Richel H, Griffiths GL, Hansen HJ, Goldenberg DM.
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [Abstract] [Full Text] [Related]

  • 24. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
    Nayak TK, Regino CA, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, Szajek LP, Brechbiel MW.
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263
    [Abstract] [Full Text] [Related]

  • 25. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.
    Zalutsky MR, Boskovitz A, Kuan CT, Pegram CN, Ayriss J, Wikstrand CJ, Buckley AF, Lipp ES, Herndon JE, McLendon RE, Bigner DD.
    Nucl Med Biol; 2012 Jan; 39(1):23-34. PubMed ID: 21958852
    [Abstract] [Full Text] [Related]

  • 26. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
    Lee FT, Rigopoulos A, Hall C, Clarke K, Cody SH, Smyth FE, Liu Z, Brechbiel MW, Hanai N, Nice EC, Catimel B, Burgess AW, Welt S, Ritter G, Old LJ, Scott AM.
    Cancer Res; 2001 Jun 01; 61(11):4474-82. PubMed ID: 11389078
    [Abstract] [Full Text] [Related]

  • 27. Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators.
    D'Huyvetter M, Aerts A, Xavier C, Vaneycken I, Devoogdt N, Gijs M, Impens N, Baatout S, Ponsard B, Muyldermans S, Caveliers V, Lahoutte T.
    Contrast Media Mol Imaging; 2012 Jun 01; 7(2):254-64. PubMed ID: 22434639
    [Abstract] [Full Text] [Related]

  • 28. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA).
    Camera L, Kinuya S, Garmestani K, Brechbiel MW, Wu C, Pai LH, McMurry TJ, Gansow OA, Pastan I, Paik CH.
    Eur J Nucl Med; 1994 Jul 01; 21(7):640-6. PubMed ID: 7957350
    [Abstract] [Full Text] [Related]

  • 29. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies.
    Camera L, Kinuya S, Garmestani K, Wu C, Brechbiel MW, Pai LH, McMurry TJ, Gansow OA, Pastan I, Paik CH.
    J Nucl Med; 1994 May 01; 35(5):882-9. PubMed ID: 8176477
    [Abstract] [Full Text] [Related]

  • 30. A systematic study on the utility of CHX-A''-DTPA-NCS and NOTA-NCS as bifunctional chelators for 177Lu radiopharmaceuticals.
    Pandey U, Gamre N, Lohar SP, Dash A.
    Appl Radiat Isot; 2017 Sep 01; 127():1-6. PubMed ID: 28478331
    [Abstract] [Full Text] [Related]

  • 31. In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts.
    Roselli M, Milenic DE, Brechbiel MW, Mirzadeh S, Pippin CG, Gansow OA, Colcher D, Schlom J.
    Cancer Biother Radiopharm; 1999 Jun 01; 14(3):209-20. PubMed ID: 10850305
    [Abstract] [Full Text] [Related]

  • 32. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.
    Reist CJ, Foulon CF, Alston K, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 1999 May 01; 26(4):405-11. PubMed ID: 10382844
    [Abstract] [Full Text] [Related]

  • 33. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
    Kelly MP, Lee ST, Lee FT, Smyth FE, Davis ID, Brechbiel MW, Scott AM.
    Prostate; 2009 Jan 01; 69(1):92-104. PubMed ID: 18942092
    [Abstract] [Full Text] [Related]

  • 34. In vitro and in vivo comparison of DTPA- and DOTA-conjugated antiferritin monoclonal antibody for imaging and therapy of pancreatic cancer.
    Sabbah EN, Kadouche J, Ellison D, Finucane C, Decaudin D, Mather SJ.
    Nucl Med Biol; 2007 Apr 01; 34(3):293-304. PubMed ID: 17383579
    [Abstract] [Full Text] [Related]

  • 35. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors.
    Vera DR, Eigner S, Henke KE, Lebeda O, Melichar F, Beran M.
    Nucl Med Biol; 2012 Jan 01; 39(1):3-13. PubMed ID: 21958849
    [Abstract] [Full Text] [Related]

  • 36. Preparation and comparative evaluation of 99mTc-labeled 2-iminothiolane modified antibodies and CITC-DTPA immunoconjugates of anti-EGF-receptor antibodies.
    Mishra AK, Iznaga-Escobar N, Figueredo R, Jain VK, Dwarakanath BS, Pérez-Rodríguez R, Sharma RK, Mathew TL.
    Methods Find Exp Clin Pharmacol; 2002 Dec 01; 24(10):653-60. PubMed ID: 12616957
    [Abstract] [Full Text] [Related]

  • 37. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
    Postema EJ, Frielink C, Oyen WJ, Raemaekers JM, Goldenberg DM, Corstens FH, Boerman OC.
    Cancer Biother Radiopharm; 2003 Aug 01; 18(4):525-33. PubMed ID: 14503946
    [Abstract] [Full Text] [Related]

  • 38. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins.
    Chappell LL, Ma D, Milenic DE, Garmestani K, Venditto V, Beitzel MP, Brechbiel MW.
    Nucl Med Biol; 2003 Aug 01; 30(6):581-95. PubMed ID: 12900284
    [Abstract] [Full Text] [Related]

  • 39. Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent 177Lu-Labeled Radiohapten.
    Vaughn BA, Lee SG, Vargas DB, Seo S, Rinne SS, Xu H, Guo HF, Le Roux AB, Gajecki L, Krebs S, Yang G, Ouerfelli O, Zanzonico PB, Fung EK, St Jean S, Carrasco SE, Jungbluth A, Cheung NKV, Larson SM, Veach DR, Cheal SM.
    J Nucl Med; 2024 Oct 01; 65(10):1611-1618. PubMed ID: 39168519
    [Abstract] [Full Text] [Related]

  • 40. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.
    Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW.
    Int J Cancer; 2011 Feb 15; 128(4):920-6. PubMed ID: 20473899
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.